Talabostat
Talabostat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target dipeptidyl peptidase 8, dipeptidyl peptidase 4, and dipeptidyl peptidase 9.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | 1 | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 2 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | 2 | — | — | — | 2 |
| Melanoma | D008545 | — | 2 | — | — | — | 2 | ||
| Prostatic neoplasms | D011471 | C61 | 1 | 1 | — | — | — | 1 | |
| Small cell carcinoma | D018288 | 1 | 1 | — | — | — | 1 | ||
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | 1 | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | 1 | — | — | — | 1 | |
| Adenocarcinoma | D000230 | — | 1 | — | — | — | 1 | ||
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | C80 | 1 | — | — | — | — | 1 | |
| Sarcoma | D012509 | 1 | — | — | — | — | 1 | ||
| Neuroblastoma | D009447 | EFO_0000621 | 1 | — | — | — | — | 1 | |
| Central nervous system neoplasms | D016543 | 1 | — | — | — | — | 1 | ||
| Germ cell and embryonal neoplasms | D009373 | 1 | — | — | — | — | 1 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TALABOSTAT |
| INN | talabostat |
| Description | Talabostat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target dipeptidyl peptidase 8, dipeptidyl peptidase 4, and dipeptidyl peptidase 9. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O |
Identifiers
| PDB | — |
| CAS-ID | 149682-77-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL67279 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | KZ1O2SH88Z (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
DPP8
DPP8
DPP4
DPP4
DPP9
DPP9
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 258 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more